MNI BRIEF: China June CPI Hits Three Month Low

RBNZ MPC SAYS OCR "HAS SIGNIFICANTLY REDUCED CPI"

MNI: RBNZ LEAVES OCR AT 5.5%

MNI: PBOC Conducts CNY2 Bln Via OMO Weds; Liquidity Unchanged

CHINA PBOC CONDUCTS CNY2 BILLION VIA 7-DAY REVERSE REPOS WEDS

MNI: PBOC Sets Yuan Parity Higher At 7.1342 Weds; -0.53% Y/Y

Headline CPI Ticks Down To 0.2% Y/Y, PPI In Line

CHINA JUNE FOOD PRICES -2.1% Y/Y VS -2.0% Y/Y MAY

CHINA JUNE CPI +0.2% Y/Y VS MEDIAN +0.4%; MAY +0.3% Y/Y: NBS

RPT-MNI: Canada Sticks To Fiscal Anchors, Spends Chunk Of Windfall

MNI BRIEF: Poilievre Calls QE 'Scam' And Would Limit BOC Remit

© 1982-2024 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

Werfen (WERFEN; NR, BBB- S, BBB- Pos) Private co

HEALTHCARE
Credit BulletsBulletHomepagemarkets-real-timeCredit

IPT out for €500m 6Y at +175.

Had some benefit from Covid on largest Hemostasis unit & under other businesses on PCR testing though seems to have emerged largely unphased (-2% & -11%yoy in both units respectively). Historical organic growth is strong, margins look in-line with peers, R&D spend (% of sales) in-line to tad weaker - though has been riding headline growth in absolute spend. Leverage run-up on recent acquisition was well tolerated by rating agencies given mgmt targets - dividend cancellation evidence of BS discipline. Maturity profile clean, no net supply here - paying down term loans.

  • Considers itself a "specialised diagnostics" player including in Hemostasis (30% market share), acute care diagnostics (17%), transfusion (20%), transplant (10%) & autoimmunity (19%).
  • It seems focused on In Vitro diagnostics (IVD) instruments, reagents (substances used to for diagnostics), clinical software solutions & education/training.
  • On Financials; Strong growth in headline revenues at 8% on 10yr CAGR (+6% organic), now at €2.1b revenues. Seems well diversified across business units & geographies (WE 36%, NA 33%) with consistent high 50's (%) profit margin and 20-30% EBITDA margins (at €517m). Recurring business generates 94% of revenue.
  • R&D; currently 8% of sales/€169m - in absolute terms strong growth in recent years (€106m in 2020).
  • On BS; Net Debt reported at €1.9b/3.5x on EBITDA with target <3x - its cancelled dividend after run-up on acquisition to bring it back in. It has tolerance for M&A but ceiling seems <4x. Reported liquidity is €633m including €300m in Cash and a RCF on remainder.
  • No net supply - €500m raise will be used to pay down term loans & will leave no significant maturities outside the €300m 26 line. Maturity profile is clean.
  • Rating agencies were happy to stay unch through Immucor acquisition given stated leverage targets - positive for future run-ups on leverage/acquisition.
303 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

IPT out for €500m 6Y at +175.

Had some benefit from Covid on largest Hemostasis unit & under other businesses on PCR testing though seems to have emerged largely unphased (-2% & -11%yoy in both units respectively). Historical organic growth is strong, margins look in-line with peers, R&D spend (% of sales) in-line to tad weaker - though has been riding headline growth in absolute spend. Leverage run-up on recent acquisition was well tolerated by rating agencies given mgmt targets - dividend cancellation evidence of BS discipline. Maturity profile clean, no net supply here - paying down term loans.

  • Considers itself a "specialised diagnostics" player including in Hemostasis (30% market share), acute care diagnostics (17%), transfusion (20%), transplant (10%) & autoimmunity (19%).
  • It seems focused on In Vitro diagnostics (IVD) instruments, reagents (substances used to for diagnostics), clinical software solutions & education/training.
  • On Financials; Strong growth in headline revenues at 8% on 10yr CAGR (+6% organic), now at €2.1b revenues. Seems well diversified across business units & geographies (WE 36%, NA 33%) with consistent high 50's (%) profit margin and 20-30% EBITDA margins (at €517m). Recurring business generates 94% of revenue.
  • R&D; currently 8% of sales/€169m - in absolute terms strong growth in recent years (€106m in 2020).
  • On BS; Net Debt reported at €1.9b/3.5x on EBITDA with target <3x - its cancelled dividend after run-up on acquisition to bring it back in. It has tolerance for M&A but ceiling seems <4x. Reported liquidity is €633m including €300m in Cash and a RCF on remainder.
  • No net supply - €500m raise will be used to pay down term loans & will leave no significant maturities outside the €300m 26 line. Maturity profile is clean.
  • Rating agencies were happy to stay unch through Immucor acquisition given stated leverage targets - positive for future run-ups on leverage/acquisition.